Literature DB >> 18571231

Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.

Abdul Rahman El Kinge, Hassan A Hatoum, Rami A Mahfouz, Zaher K Otrock, Elias Jabbour, Hagop Kantarjian, Ali Bazarbachi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18571231     DOI： 10.1016/j.leukres.2008.05.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  1 in total

1.  Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.

Authors:  Motoshi Ichikawa; Akira Hangaishi; Yasuhito Nannya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-10-28       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.